AAA
ZYNE

Affinity Asset Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Affinity Asset Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,285
Closed -$62K – 83
2021
Q1 		$62K Hold
13,285
– – 0.02% 72
2020
Q4 		$44K Buy
+13,285
New +$50.4K 0.02% 62

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Affinity Asset Advisors's ZYNE Position: Q2 2021 in Review

Affinity Asset Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2021, closing a stake of 13,285 shares — an estimated $62K sold.

Affinity Asset Advisors first reported a position in ZYNE in Q4 2020 and held it in 2 quarters. The position peaked at $62K in Q1 2021. 65 funds tracked by Wall St. Rank hold ZYNE as of Q2 2021.

  • Affinity Asset Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 13,285 Zynerba Pharmaceuticals, Inc shares in Q2 2021, an estimated $62K.
  • Affinity Asset Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2020 and held it in 2 quarters.
  • Affinity Asset Advisors's Zynerba Pharmaceuticals, Inc position peaked at $62K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2021.

Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.